Comparative risk of severe constipation in patients treated with opioids for non-cancer pain: a retrospective cohort study in Northwest England
Comparative risk of severe constipation in patients treated with opioids for non-cancer pain: a retrospective cohort study in Northwest England
Background: Constipation is a frequent adverse event associated with opioid medications that can have a considerable impact on patients’ quality of life. In patients who require opioids for pain relief, less is known about the risk conferred by specific opioids given their diverse pharmacology and the effect of daily dose and potency. The aim of the study was to evaluate the comparative risk of severe constipation by opioid type and dose in patients with non-cancer pain admitted to hospital. Methods: We conducted a retrospective cohort study using hospital electronic health records in Northwest England between December 1, 2009, and December 31, 2020. Patients who were ≥ 18 years and without a history of cancer were included. Opioid exposure was measured using administered drug information in hospital. The outcome was a severe constipation event defined as administration of an enema or suppository. Incidence rates by opioid use status, type of opioid class and morphine milligram equivalent (MME) per day were calculated, and a Cox regression model was used to determine associations with incident constipation after adjusting for confounders. Results: The study included 80,475 eligible patients who were administered an opioid in hospital. Compared to codeine, morphine (HR 1.59, 95% CI 1.45–1.74), oxycodone (HR 1.46, 95% CI 1.32–1.63), fentanyl (HR 1.37, 95% CI 1.14–1.64) and combination opioids (HR 1.85, 95% CI 1.66–2.06) were associated with a higher risk of constipation in the fully adjusted models. Tramadol demonstrated a significantly lower risk compared to codeine (HR 0.80, 95% CI 0.64–1.00). Higher opioid doses of more than ≥ 50 MME/day in comparison to < 50 MME/day were associated with an increased risk of constipation (compared to < 50 MME/day, 50 to < 120 MME/day: HR 1.95, 95% CI 1.78–2.15; ≥ 120 MME/day: HR 1.45, 95% CI 1.32–1.60). Conclusions: Morphine, oxycodone, fentanyl and combination opioids administration were associated with a significantly higher risk of severe constipation compared to codeine. Tramadol was associated with the lowest risk of the outcome compared to codeine. Patients on ≥ 50 MME/day experienced a higher risk of severe constipation compared to those on < 50 MME/day. These results can be used to guide better shared decisions with patients to balance benefit and harms of specific opioid types and doses.
Adverse events, Chronic pain, Constipation, Drug safety, Electronic health records, Morphine milligram equivalents, Opiates, Opioid-related harms, Opioids
Yimer, Belay Birlie
35af844b-99da-44ae-959a-edfe713eb3c3
Soomro, Mehreen
845965a2-071f-41d0-a00c-bad9cab3799f
McBeth, John
98012716-66ba-480b-9e43-ac53b51dce61
Medina, Carlos Raul Ramirez
e4d5b0b2-d3f1-43b8-a1c7-cca825b51150
Lunt, Mark
d8ac296a-c589-4d9d-b4c4-9f3f219b772c
Dixon, William G.
8fcb2256-4094-4f58-9777-4248ad245166
Jani, Meghna
cb236cda-9d7a-4a78-a79f-fdf9b7d77022
16 June 2025
Yimer, Belay Birlie
35af844b-99da-44ae-959a-edfe713eb3c3
Soomro, Mehreen
845965a2-071f-41d0-a00c-bad9cab3799f
McBeth, John
98012716-66ba-480b-9e43-ac53b51dce61
Medina, Carlos Raul Ramirez
e4d5b0b2-d3f1-43b8-a1c7-cca825b51150
Lunt, Mark
d8ac296a-c589-4d9d-b4c4-9f3f219b772c
Dixon, William G.
8fcb2256-4094-4f58-9777-4248ad245166
Jani, Meghna
cb236cda-9d7a-4a78-a79f-fdf9b7d77022
Yimer, Belay Birlie, Soomro, Mehreen, McBeth, John, Medina, Carlos Raul Ramirez, Lunt, Mark, Dixon, William G. and Jani, Meghna
(2025)
Comparative risk of severe constipation in patients treated with opioids for non-cancer pain: a retrospective cohort study in Northwest England.
BMC Medicine, 23 (1), [288].
(doi:10.1186/s12916-025-04118-7).
Abstract
Background: Constipation is a frequent adverse event associated with opioid medications that can have a considerable impact on patients’ quality of life. In patients who require opioids for pain relief, less is known about the risk conferred by specific opioids given their diverse pharmacology and the effect of daily dose and potency. The aim of the study was to evaluate the comparative risk of severe constipation by opioid type and dose in patients with non-cancer pain admitted to hospital. Methods: We conducted a retrospective cohort study using hospital electronic health records in Northwest England between December 1, 2009, and December 31, 2020. Patients who were ≥ 18 years and without a history of cancer were included. Opioid exposure was measured using administered drug information in hospital. The outcome was a severe constipation event defined as administration of an enema or suppository. Incidence rates by opioid use status, type of opioid class and morphine milligram equivalent (MME) per day were calculated, and a Cox regression model was used to determine associations with incident constipation after adjusting for confounders. Results: The study included 80,475 eligible patients who were administered an opioid in hospital. Compared to codeine, morphine (HR 1.59, 95% CI 1.45–1.74), oxycodone (HR 1.46, 95% CI 1.32–1.63), fentanyl (HR 1.37, 95% CI 1.14–1.64) and combination opioids (HR 1.85, 95% CI 1.66–2.06) were associated with a higher risk of constipation in the fully adjusted models. Tramadol demonstrated a significantly lower risk compared to codeine (HR 0.80, 95% CI 0.64–1.00). Higher opioid doses of more than ≥ 50 MME/day in comparison to < 50 MME/day were associated with an increased risk of constipation (compared to < 50 MME/day, 50 to < 120 MME/day: HR 1.95, 95% CI 1.78–2.15; ≥ 120 MME/day: HR 1.45, 95% CI 1.32–1.60). Conclusions: Morphine, oxycodone, fentanyl and combination opioids administration were associated with a significantly higher risk of severe constipation compared to codeine. Tramadol was associated with the lowest risk of the outcome compared to codeine. Patients on ≥ 50 MME/day experienced a higher risk of severe constipation compared to those on < 50 MME/day. These results can be used to guide better shared decisions with patients to balance benefit and harms of specific opioid types and doses.
Text
s12916-025-04118-7
- Version of Record
More information
Accepted/In Press date: 6 May 2025
Published date: 16 June 2025
Additional Information:
Publisher Copyright:
© The Author(s) 2025.
Keywords:
Adverse events, Chronic pain, Constipation, Drug safety, Electronic health records, Morphine milligram equivalents, Opiates, Opioid-related harms, Opioids
Identifiers
Local EPrints ID: 503834
URI: http://eprints.soton.ac.uk/id/eprint/503834
ISSN: 1741-7015
PURE UUID: 0311ba1d-48fd-4187-8631-d41731db48da
Catalogue record
Date deposited: 14 Aug 2025 16:47
Last modified: 22 Aug 2025 02:43
Export record
Altmetrics
Contributors
Author:
Belay Birlie Yimer
Author:
Mehreen Soomro
Author:
John McBeth
Author:
Carlos Raul Ramirez Medina
Author:
Mark Lunt
Author:
William G. Dixon
Author:
Meghna Jani
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics